Aparito believes that better patient experiences provide better study outcomes.
Design & Strategise
Support & input on study design through each phase by our trusted in-house regulatory experts
Strategic support to ensure regulatory buy-in through use of innovative solutions and data capture
Engage / Operationalise
Full stack platform that is ISO13485 / IEC 27001:2013 accredited and FDA 21 CFR Part 11, HIPAA and GDPR compliant
Mobile App & Wearables
Ability to remotely collect patient data and integrate with any wearable device via a Bluetooth connection to collect data in real time
Real time patient data 24/7/365 that can be individual or cohort level for analysis and publication
Our CEO, Elin Haf, began her journey 24 years ago at Great Ormond Street Hospital for Children in London. She worked with paediatric patients suffering from life-threatening and life-limiting diseases who were enrolled in clinical trials as their last resort to better health. She saw the hope and hurdles families faced travelling extensive distances for tests, follow-ups and appointments: if the patient didn’t live close to the research centre, there was significant cost and disruption to the family’s life. Unfortunately, that strain caused many families to drop out of the studies.
Determined to change the system, Elin went on to attain a PhD focused on child-friendly, non-invasive assessments for orphan drugs in paediatrics and rare disease and later became a regulator at the European Medicine Agency. Unfortunately, the tools weren’t there to make the necessary changes but she didn’t give up.
Elin was determined to help people with rare diseases get access to treatments that could genuinely improve the quality of their lives and bring new and innovative drugs to market in the shortest possible time.
Aparito’s Atom5™ is Elin’s solution for improving clinical trials. Initially designed for paediatric and rare diseases, the platform can enhance compliance and the potential to improve the outcomes of any clinical trial. Its data-driven, decentralised platform allows for clinical studies to be done anywhere, anytime allowing patients and their caregivers to participate in research from the comfort of their own homes.